<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01371877</url>
  </required_header>
  <id_info>
    <org_study_id>271-11-FB</org_study_id>
    <nct_id>NCT01371877</nct_id>
  </id_info>
  <brief_title>The Role of Vitamin D in Chronic Urticaria and Angioedema Treatment</brief_title>
  <official_title>The Role of Vitamin D in Chronic Urticaria and Angioedema Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Nebraska</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study was designed based on our hypothesis that vitamin D plays an important
      role in chronic urticaria and that high dose supplementation with vitamin D in subjects with
      chronic urticaria will improve clinical response.

      This clinical study will investigate our hypothesis in three Specific Aims:

        1. Determine whether high dosing vitamin D supplementation (4000 IU/day) reduces medication
           usage (primary outcome) and urticaria severity score (secondary outcome) in subjects
           with chronic urticaria as compared to low dosing (600 IU/day).

        2. Determine if high dosing of vitamin D (4000 IU/day) is safe and well-tolerated in
           subjects with chronic urticaria with or without baseline vitamin D deficiency.

        3. Investigate whether there is an association with serum 25-hydroxyvitamin D levels,
           vitamin D receptor mRNA expression, and chronic urticaria severity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this pilot, 12 week, clinical research study is to determine if
      supplementation with Vitamin D will improve the clinical outcome in subjects with chronic
      urticaria and angioedema (CUA). Vitamin D is a key element in the regulation of immune system
      responses, and vitamin D could play an important role in the treatment of CUA. Recently, we
      published that there is an important association with CUA and serum 25-hydroxy vitamin D
      (25OHD). Namely, vitamin D levels in subjects with CUA were significantly lower as compared
      to subjects with an alternative allergic disorder, allergic rhinitis. There is now one other
      observational report that supplementation with vitamin D (50,000/wk) in subjects CUA resulted
      in clinical improvement; however, there was only one treatment arm and optimal serum 25OHD
      required to obtain benefit was not investigated.

      This current study is a double-blinded, prospective, interventional study that seeks to
      recruit adult subjects with physician-diagnosed CUA and randomize subjects to either the
      recommended dietary allowance (Vitamin D 600 IU/day) or the recommended upper limit of intake
      (Vitamin D 4000 IU/day). Subjects will answer a questionnaire to collect information
      regarding demographics, previous diagnostic tests, medications, and complete an urticaria
      severity score (USS). Information from the medical record: weight, height, body mass index
      (BMI), thyroid stimulating hormone (TSH), free thyroxine (T4), thyroid autoantibodies,
      urticaria autoimmune testing (CD203c results), anti-nuclear antibody (ANA), urinalysis, and
      allergy skin prick testing, which are part of the CUA evaluation will be obtained. Subjects
      will have research blood draws for serum 25OHD level, iPTH, calcium, phosphorus, albumin,
      urine calcium, and vitamin D receptor (VDR) gene expression. All subjects will receive
      standard-of-care therapy according to the 2009 Third International Consensus Meeting on
      Urticaria position guidelines. Follow-up visits for medication usage, urticaria severity
      score, and serum and urine safety monitoring will be at 6 and 12 weeks.

      The hypothesis of this study is that high dosing of vitamin D will result in clinical
      improvement in subjects with CUA. The primary clinical endpoint is medication usage, and the
      secondary outcomes are urticaria severity score and prednisone rescue use. We will explore if
      threshold serum 25OHD levels correlate and VDR expression correlate to clinical outcomes, and
      to determine power analysis to conduct a larger scale study. Finally, the study aims to
      determine if vitamin D supplementation is safe and well-tolerated in subjects with CUA.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2011</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Medication Usage</measure>
    <time_frame>12 week intervention</time_frame>
    <description>The Unit of Measure is Efficacy. The primary outcome of this study is to determine if vitamin D supplementation reduces the medication usage in subjects with CUA. Thus, for the outcome of reduction in pills, at 12 weeks, subjects whose pill usage decreases by 2 or more pills per day will be classified as improved. Subjects whose pill consumption did not change or increased will be classified as unchanged.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Urticaria Severity Score at 3 Months</measure>
    <time_frame>3 month intervention</time_frame>
    <description>The Unit of Measure is Efficacy. The Total Urticaria Severity Score (USS) ranges from 0 to 93, higher scores = worse symptoms. This secondary outcome of this study is to determine if high dose vitamin D supplementation improves the urticaria severity score (USS). The change in USS will be compared between the groups using the independent sample t-test (assuming the distribution is normal). Logistic regression and multiple linear regression will be used to adjust for possible confounders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>3 month study trial</time_frame>
    <description>Unit of Measure is Safety and Tolerability. The number of participants with adverse events will be compared between the groups using the independent sample t-test (assuming the distribution is normal).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Urticaria</condition>
  <condition>Angioedema</condition>
  <condition>Hives</condition>
  <condition>Swelling</condition>
  <arm_group>
    <arm_group_label>Vitamin D3 4000 IU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomized 1:1 to high dose vitamin D defined as 4000 IU per day for 3 months.
Subjects will be given Vitamin D3 supplementation at 4000 IU daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D3 600 IU</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be randomized 1:1 to low dose vitamin D as defined as 600 IU per day for 3 months.
Subjects will be given Vitamin D3 supplementation at 600 IU daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>Vitamin D 4000 IU per day for 3 months</description>
    <arm_group_label>Vitamin D3 4000 IU</arm_group_label>
    <other_name>cholecalciferol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>Vitamin D 600 IU per day</description>
    <arm_group_label>Vitamin D3 600 IU</arm_group_label>
    <other_name>cholecalciferol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects will be included if they have physician-diagnosed chronic urticaria and/or
             angioedema (CUA). CUA is defined by having urticarial wheals (hives) and/or angioedema
             (dermal swelling) on a daily or almost daily for more than 6 weeks. Patients with CUA
             also having signs of dermatographism and/or delayed-pressure urticaria will be
             included in the study. Subjects with history of intolerance to non-steroidal
             anti-inflammatory drugs will be included but warned not to take this drug class
             (acetaminophen will be allowed instead).

        Exclusion Criteria:

          -  Subjects will be excluded if:

               1. They are not capable of answering the questionnaire.

               2. Subjects with a pure physical or allergic urticarias, and/or hereditary and
                  acquired angioedema (C1 esterase inhibitor deficiency). These subjects will be
                  excluded as the etiology of their disease is known.

               3. Pregnant or lactating women. All child-bearing women will be asked (verbally and
                  on the questionnaire) if they are pregnant or lactating. If they answer yes, they
                  will be excluded. As there is no risk or harm to the pregnant or lactating woman,
                  a urine pregnancy test will not be used.

               4. Subjects with any clinically significant abnormality in biochemistry testing,
                  and/or hypercalcemia (calcium &gt; 10.3 mg/dl) or renal insufficiency (GFR&lt; 50
                  ml/min).

               5. Subjects with a history of primary hyperparathyroidism, renal tubular acidosis,
                  sarcoidosis, granulomatous disease, or malignancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jill A Poole, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nebraska</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-5300</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Thorp WA, Goldner W, Meza J, Poole JA. Reduced vitamin D levels in adult subjects with chronic urticaria. J Allergy Clin Immunol. 2010 Aug;126(2):413; author reply 413-4. doi: 10.1016/j.jaci.2010.04.040.</citation>
    <PMID>20621341</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2011</study_first_submitted>
  <study_first_submitted_qc>June 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2011</study_first_posted>
  <results_first_submitted>December 1, 2014</results_first_submitted>
  <results_first_submitted_qc>December 12, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 16, 2014</results_first_posted>
  <last_update_submitted>August 30, 2017</last_update_submitted>
  <last_update_submitted_qc>August 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Nebraska</investigator_affiliation>
    <investigator_full_name>Jill Poole, MD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>urticaria</keyword>
  <keyword>angioedema</keyword>
  <keyword>hive</keyword>
  <keyword>swelling</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urticaria</mesh_term>
    <mesh_term>Angioedema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>High Dose Vitamin D</title>
          <description>Subjects will be randomized 1:1 to high dose vitamin D defined as 4000 IU per day for 3 months.
Vitamin D: Vitamin D 4000 IU per day for 3 months</description>
        </group>
        <group group_id="P2">
          <title>Low Dose Vitamin D</title>
          <description>Subjects will be randomized 1:1 to low dose vitamin D as defined as 600 IU per day for 3 months.
Vitamin D: Vitamin D 600 IU per day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>3 for unknown reasons and 1 pregnant</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>High Dose Vitamin D</title>
          <description>Subjects will be randomized 1:1 to high dose vitamin D defined as 4000 IU per day for 3 months.
Vitamin D: Vitamin D 4000 IU per day for 3 months</description>
        </group>
        <group group_id="B2">
          <title>Low Dose Vitamin D</title>
          <description>Subjects will be randomized 1:1 to low dose vitamin D as defined as 600 IU per day for 3 months.
Vitamin D: Vitamin D 600 IU per day</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.9" lower_limit="19" upper_limit="79"/>
                    <measurement group_id="B2" value="43.1" lower_limit="20" upper_limit="72"/>
                    <measurement group_id="B3" value="43.5" lower_limit="19" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline vitamin D level</title>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.86" spread="10.1"/>
                    <measurement group_id="B2" value="37.2" spread="15.5"/>
                    <measurement group_id="B3" value="33.0" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Medication Usage</title>
        <description>The Unit of Measure is Efficacy. The primary outcome of this study is to determine if vitamin D supplementation reduces the medication usage in subjects with CUA. Thus, for the outcome of reduction in pills, at 12 weeks, subjects whose pill usage decreases by 2 or more pills per day will be classified as improved. Subjects whose pill consumption did not change or increased will be classified as unchanged.</description>
        <time_frame>12 week intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose Vitamin D</title>
            <description>Subjects will be randomized 1:1 to high dose vitamin D defined as 4000 IU per day for 3 months.
Vitamin D: Vitamin D 4000 IU per day for 3 months</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Vitamin D</title>
            <description>Subjects will be randomized 1:1 to low dose vitamin D as defined as 600 IU per day for 3 months.
Vitamin D: Vitamin D 600 IU per day</description>
          </group>
        </group_list>
        <measure>
          <title>Medication Usage</title>
          <description>The Unit of Measure is Efficacy. The primary outcome of this study is to determine if vitamin D supplementation reduces the medication usage in subjects with CUA. Thus, for the outcome of reduction in pills, at 12 weeks, subjects whose pill usage decreases by 2 or more pills per day will be classified as improved. Subjects whose pill consumption did not change or increased will be classified as unchanged.</description>
          <units>number of pills/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline medication usage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="2.6"/>
                    <measurement group_id="O2" value="4.6" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 month medication usage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="2.9"/>
                    <measurement group_id="O2" value="4.9" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Urticaria Severity Score at 3 Months</title>
        <description>The Unit of Measure is Efficacy. The Total Urticaria Severity Score (USS) ranges from 0 to 93, higher scores = worse symptoms. This secondary outcome of this study is to determine if high dose vitamin D supplementation improves the urticaria severity score (USS). The change in USS will be compared between the groups using the independent sample t-test (assuming the distribution is normal). Logistic regression and multiple linear regression will be used to adjust for possible confounders.</description>
        <time_frame>3 month intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High Dose Vitamin D</title>
            <description>Subjects will be randomized 1:1 to high dose vitamin D defined as 4000 IU per day for 3 months.
Vitamin D: Vitamin D 4000 IU per day for 3 months</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Vitamin D</title>
            <description>Subjects will be randomized 1:1 to low dose vitamin D as defined as 600 IU per day for 3 months.
Vitamin D: Vitamin D 600 IU per day</description>
          </group>
        </group_list>
        <measure>
          <title>Total Urticaria Severity Score at 3 Months</title>
          <description>The Unit of Measure is Efficacy. The Total Urticaria Severity Score (USS) ranges from 0 to 93, higher scores = worse symptoms. This secondary outcome of this study is to determine if high dose vitamin D supplementation improves the urticaria severity score (USS). The change in USS will be compared between the groups using the independent sample t-test (assuming the distribution is normal). Logistic regression and multiple linear regression will be used to adjust for possible confounders.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Total Urticaria Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.14" spread="2.36"/>
                    <measurement group_id="O2" value="40.1" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 week Total Urticaria Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.48" spread="3.34"/>
                    <measurement group_id="O2" value="29.24" spread="3.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 month Total Urticaria Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" spread="2.9"/>
                    <measurement group_id="O2" value="24.1" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Unit of Measure is Safety and Tolerability. The number of participants with adverse events will be compared between the groups using the independent sample t-test (assuming the distribution is normal).</description>
        <time_frame>3 month study trial</time_frame>
        <population>No significant adverse events. All subjects in the high vitamin D3 group completed the study; 4 subjects in the low vitamin D3 600 IU/day withdrew from the study (1 for pregnancy and 3 unknown). There was no evidence of hypercalcemia.</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose Vitamin D</title>
            <description>Subjects will be randomized 1:1 to high dose vitamin D defined as 4000 IU per day for 3 months.
Vitamin D: Vitamin D 4000 IU per day for 3 months</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Vitamin D</title>
            <description>Subjects will be randomized 1:1 to low dose vitamin D as defined as 600 IU per day for 3 months.
Vitamin D: Vitamin D 600 IU per day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Unit of Measure is Safety and Tolerability. The number of participants with adverse events will be compared between the groups using the independent sample t-test (assuming the distribution is normal).</description>
          <population>No significant adverse events. All subjects in the high vitamin D3 group completed the study; 4 subjects in the low vitamin D3 600 IU/day withdrew from the study (1 for pregnancy and 3 unknown). There was no evidence of hypercalcemia.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected continuously and reported to data safety board every 3 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>High Dose Vitamin D</title>
          <description>Subjects will be randomized 1:1 to high dose vitamin D defined as 4000 IU per day for 3 months.
Vitamin D: Vitamin D 4000 IU per day for 3 months</description>
        </group>
        <group group_id="E2">
          <title>Low Dose Vitamin D</title>
          <description>Subjects will be randomized 1:1 to low dose vitamin D as defined as 600 IU per day for 3 months.
Vitamin D: Vitamin D 600 IU per day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jill Poole</name_or_title>
      <organization>University of Nebraska Medical Center</organization>
      <phone>402-559-4087</phone>
      <email>japoole@unmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

